Clinical Trials (Phase I)

Found 15,990 articles

• 

  Is an mRNA Flu Vaccine on the Horizon?

  6/23/2021

  The two companies will assess the safety and immunogenicity of the vaccine candidate, which codes for the hemagglutinin protein in the A/H3N2 strain of the seasonal flu virus.

• Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter

  6/23/2021

  Cocrystal Pharma, Inc. announces the completion of IND-enabling studies with its potent, broad-spectrum PB2 inhibitor CC-42344 for the treatment of seasonal and pandemic influenza A and plans to initiate Phase 1.

• IGC Completes the Final Cohort of Its Phase 1 Clinical Trial on Alzheimer’s Patients

  6/23/2021

  India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announces today it has completed Cohort 3 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease

• Seal Rock Therapeutics Announces Initiation of Phase 1 Clinical Trial of ASK1 Inhibitor SRT-015 for NASH

  6/23/2021

  Seal Rock Therapeutics, Inc. today announced dosing of the first healthy volunteer in a Phase 1 clinical trial of SRT-015.

• PureTech Founded Entity Karuna Therapeutics Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy Elderly Volunteers

  6/23/2021

  PureTech Health today announced data from its completed Phase 1b trial evaluating the safety and tolerability of KarXT (xanomeline-trospium) in healthy elderly volunteers.

• Medicenna Announces Submission of Clinical Trial Application in Australia for a Phase 1/2 Study of MDNA11

  6/23/2021

  Medicenna Therapeutics Corp. today announced that it has submitted a clinical trial application to a Human Research Ethics Committee (HREC) in Australia to initiate a Phase 1/2 clinical study of MDNA11.

• Noveome Biotherapeutics, Inc. Commences Phase 1 Clinical Study of ST266 Application for Infectious Disease (including COVID-19)

  6/23/2021

  Noveome Biotherapeutics, Inc. (Noveome) announced that it has commenced its Phase 1 clinical trial by dosing its first patient.

• Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors

  6/23/2021

  Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that the first patient has been dosed in a new Phase 1 arm of the ongoing Phase 1/2 clinical trial of RTX-240 in combination with KEYTRUDA®

• Karuna Therapeutics Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy Elderly Volunteers

  6/23/2021

  Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced data from its completed Phase 1b trial evaluating the safety and tolerability of KarXT in healthy elderly volunteers.

• Antios Therapeutics’ ATI-2173 Demonstrates Potent Antiviral Activity and Evidence of Off-Treatment Sustained Viral Suppression in Chronic HBV Patients

  6/23/2021

  Antios Therapeutics, Inc. (“Antios”) today announced pharmacokinetic (PK), safety and efficacy data from a Phase 1b clinical trial of ATI-2173.

• DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 (EASL)

  6/23/2021

   DURECT Corporation (Nasdaq: DRRX) today announced the presentation of additional clinical data from a DUR-928 Phase 1b trial in non-alcoholic steatohepatitis (NASH) and a Phase 1 trial in subjects with hepatic impairment (HI) as part of two posters at the 2021 International Liver Conference (EASL

• Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress

  6/23/2021

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented positive interim results from AROHSD1001.

• Seven and Eight Biopharmaceuticals Inc. Announces the First Patient Treated in a First-in-Human Clinical Trial of the TLR7/8 dual agonist BDB018 in Advanced Solid Tumors

  6/23/2021

  Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, announced today that the first patient was treated in a First-in-Human Phase 1 clinical trial evaluating BDB018 in advanced solid tumors.

• Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment

  6/23/2021

  Clovis Oncology, Inc. announced today that the first clinical site for the Phase 1/2 LuMIERE study of FAP-2286.

• Editas Medicine Announces Enrollment of the First Pediatric Cohort in the BRILLIANCE Clinical Trial of EDIT-101 for the Treatment of LCA10 Following IDMC Endorsement

  6/23/2021

  Editas Medicine, Inc., a leading genome editing company, announced that centers are now enrolling the first of two planned pediatric cohorts in the Phase 1/2 BRILLIANCE clinical trial of EDIT-101 following the Independent Data Monitoring Committee endorsement to proceed.

• Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021

  6/23/2021

  Brii Biosciences today announced final results from a Phase 1b/2a study on BRII-179 (VBI-2601), a novel recombinant, protein-based immunotherapeutic candidate, in patients with chronic hepatitis B virus (HBV) infection.

• XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer

  6/23/2021

  XBiotech Inc. has enrolled the first patient in its 1-BETTER study, a randomized, double-blind, placebo-controlled clinical study to evaluate XB2001 in combination chemotherapy for treatment of Pancreatic Cancer.

• Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven

  6/23/2021

  Sosei Group Corporation announces that the first healthy subject has been dosed with HTL0022562 in a Phase 1 clinical study.

• First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer

  6/22/2021

  Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that a first patient has been dosed in a Phase I study of TLX250-CDx (89Zr-DFO-girentuximab) in patients with urothelial carcinoma or bladder cancer at Fiona Stanley Hospital in Perth, Western Australia.

• Keros Therapeutics Announces Preliminary Results from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes

  6/22/2021

  Keros Therapeutics, Inc. today announced preliminary results from Cohorts 1 and 2 of its Phase 2 clinical trial evaluating KER-050